Cognition Therapeutics Announces Publication of Complete Results from Phase 1 Clinical Trial of Elayta™
February 19, 2019 08:02 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...
Cognition Therapeutics Presenting Evidence for Elayta Synaptic Protection in Alzheimer’s Patients at Combined AAT-AD/PD Focus Meeting
March 14, 2018 10:33 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, March 14, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at Sachs Neuroscience Innovation Forum
January 04, 2018 08:05 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...